• Vaccine Name: inactivated Brucella abortus strain 2308 cell envelope vaccine
• Target Pathogen: Brucella spp.
• Target Disease: Brucellosis
• Vaccine Ontology ID: VO_0009067
• Type: Inactivated vaccine
• Status: Research
• Host Species for Licensed Use: Cattle
• Host Species as Laboratory Animal Model: Mus musculus (BALB/c mouse)
• Adjuvant: phosphate-buffered saline, incomplete Freund adjuvant, or trehalose dimycolate and muramyl dipeptide
• Preparation: Cell envelopes administered in phosphate-buffered saline, incomplete Freund adjuvant, or TDM and MDP adjuvant. (Montaraz et al., 1986)
• Description: Cell envelopes from virulent strain 2308 were used as nonliving vaccine antigens administered with various adjuvants. Efficacy: Equivalent protection at 1 week post-infection regardless of adjuvant used. Immune response: Early protection largely due to O antibodies; T cell-mediated immunity had a subsidiary role. (Montaraz et al., 1986)

Mouse Response

• Host Strain: BALB/c
• Vaccination Protocol: Mice were vaccinated with Brucella abortus cell-envelope antigens formulated with different adjuvants. (Montaraz et al., 1986)
• Immune Response: Early protection largely due to O antibodies; T cell-mediated immunity had a subsidiary role. (Montaraz et al., 1986)
• Challenge Protocol: Mice vaccinated and challenged with strain 2308; protection assessed by spleen bacterial counts at 1 week post-infection. (Montaraz et al., 1986)
• Efficacy: Equivalent protection at 1 week post-infection regardless of adjuvant used. (Montaraz et al., 1986)
• Description: Mice vaccinated and challenged with strain 2308; protection assessed by spleen bacterial counts at 1 week post-infection. (Montaraz et al., 1986)